XERIS BIOPHARMA HOLDINGS, INC. (XERS) Operating cash flow 2020–2025
XERIS BIOPHARMA HOLDINGS, INC. (XERS) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$28.6MFY2025 · since FY2020: -$80.6M → $28.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $28.6M | +177.4% |
| FY2024 | -$37.0M | +21.4% |
| FY2023 | -$47.0M | +54.3% |
| FY2022 | -$102.9M | -7.7% |
| FY2021 | -$95.5M | -18.6% |
| FY2020 | -$80.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More XERS financial trends
XERS RevenueXERS Net incomeXERS Net marginXERS Gross profitXERS Gross marginXERS Operating incomeXERS Operating marginXERS Free cash flowXERS Capital expendituresXERS Return on equityXERS Stock buybacksXERS Dividends paidXERS Total assetsXERS Total liabilitiesXERS Shareholders’ equityXERS overview →